NTLA
Price
$8.99
Change
+$0.47 (+5.52%)
Updated
Nov 28 closing price
Capitalization
1.04B
81 days until earnings call
Intraday BUY SELL Signals
PLX
Price
$1.78
Change
-$0.05 (-2.73%)
Updated
Nov 28 closing price
Capitalization
143.15M
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NTLA vs PLX

Header iconNTLA vs PLX Comparison
Open Charts NTLA vs PLXBanner chart's image
Intellia Therapeutics
Price$8.99
Change+$0.47 (+5.52%)
Volume$3.71M
Capitalization1.04B
Protalix BioTherapeutics
Price$1.78
Change-$0.05 (-2.73%)
Volume$294.69K
Capitalization143.15M
NTLA vs PLX Comparison Chart in %
NTLA
Daily Signal:
Gain/Loss:
PLX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NTLA vs. PLX commentary
Nov 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a StrongBuy and PLX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 30, 2025
Stock price -- (NTLA: $8.99 vs. PLX: $1.78)
Brand notoriety: NTLA and PLX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 43% vs. PLX: 36%
Market capitalization -- NTLA: $1.04B vs. PLX: $143.15M
NTLA [@Biotechnology] is valued at $1.04B. PLX’s [@Biotechnology] market capitalization is $143.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePLX’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PLX’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than PLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 6 TA indicator(s) are bullish while PLX’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 6 bullish, 4 bearish.
  • PLX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than PLX.

Price Growth

NTLA (@Biotechnology) experienced а +9.50% price change this week, while PLX (@Biotechnology) price change was +1.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.92%. For the same industry, the average monthly price growth was +1.16%, and the average quarterly price growth was +72.91%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 19, 2026.

PLX is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+6.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.04B) has a higher market cap than PLX($143M). PLX YTD gains are higher at: -5.319 vs. NTLA (-22.899). PLX has higher annual earnings (EBITDA): 10.4M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. PLX (33.4M). PLX has less debt than NTLA: PLX (5.35M) vs NTLA (103M). PLX has higher revenues than NTLA: PLX (61.9M) vs NTLA (52.9M).
NTLAPLXNTLA / PLX
Capitalization1.04B143M728%
EBITDA-501.87M10.4M-4,826%
Gain YTD-22.899-5.319430%
P/E RatioN/A22.25-
Revenue52.9M61.9M85%
Total Cash460M33.4M1,377%
Total Debt103M5.35M1,926%
FUNDAMENTALS RATINGS
NTLA vs PLX: Fundamental Ratings
NTLA
PLX
OUTLOOK RATING
1..100
7087
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9551
PRICE GROWTH RATING
1..100
6560
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (19) in the Biotechnology industry is somewhat better than the same rating for PLX (70) in the Servicestothe Health Industry industry. This means that NTLA’s stock grew somewhat faster than PLX’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PLX (100) in the Servicestothe Health Industry industry. This means that NTLA’s stock grew similarly to PLX’s over the last 12 months.

PLX's SMR Rating (51) in the Servicestothe Health Industry industry is somewhat better than the same rating for NTLA (95) in the Biotechnology industry. This means that PLX’s stock grew somewhat faster than NTLA’s over the last 12 months.

PLX's Price Growth Rating (60) in the Servicestothe Health Industry industry is in the same range as NTLA (65) in the Biotechnology industry. This means that PLX’s stock grew similarly to NTLA’s over the last 12 months.

PLX's P/E Growth Rating (97) in the Servicestothe Health Industry industry is in the same range as NTLA (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPLX
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
61%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signal:
Gain/Loss:
PLX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BAFHX18.880.17
+0.91%
Brown Advisory WMC Strat Eurp Eq Instl
JGINX82.900.43
+0.52%
Janus Henderson Growth And Income I
FSCIX36.750.12
+0.33%
Fidelity Advisor Small Cap I
FNKCX16.350.03
+0.18%
Frank Value C
RMBLX54.660.04
+0.07%
RMB Mendon Financial Services I

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+5.52%
VCYT - NTLA
69%
Closely correlated
-0.78%
BEAM - NTLA
60%
Loosely correlated
+1.20%
CRSP - NTLA
59%
Loosely correlated
+0.32%
AXON - NTLA
55%
Loosely correlated
+1.31%
EDIT - NTLA
49%
Loosely correlated
+0.42%
More

PLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLX has been loosely correlated with IOVA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then IOVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
-2.73%
IOVA - PLX
44%
Loosely correlated
+1.23%
ADMA - PLX
34%
Loosely correlated
+0.21%
STOK - PLX
31%
Poorly correlated
-0.96%
ZNTL - PLX
31%
Poorly correlated
-0.69%
CPRX - PLX
31%
Poorly correlated
-0.09%
More